#KyorinPharmaceutical

For the third quarter of the fiscal year ending March 2026, net sales were ¥92,456 million (3.6% increase YoY), operating income was ¥4,609 million (47.9% increase YoY), and net income attributable to owners of the parent was ¥4,119 million (68.9% increase YoY).

Manufacturing and marketing approval obtained from the Ministry of Health, Labour and Welfare for the Influenza Virus Nucleic Acid Kit "GeneSoC FluA/B Detection Kit," scheduled for sales launch in the first half of fiscal 2026.